Flow Cytometry Market Research Report Information Forecast to 2032

List of Tables

Market Overview

The Flow Cytometry Market is expected to register a healthy CAGR of 7.47% during the forecast period.

The elements that are driving the development of the worldwide market are the rising pervasiveness of ongoing infections and developing interest for purpose in care testing.

There has been a critical expansion in the pervasiveness of ongoing sicknesses like malignant growth, cardiovascular illnesses, immune system infections, irresistible sicknesses, and others which has prompted an expanded interest for cutting edge symptomatic and research devices, for example, flow cytometry. For example, as per World Wellbeing Association (WHO) figures, malignant growth is the essential or second driving reason for death in 112 of 183 countries before the age of 70. Likewise, GLOBOCAN 2020 assessments of disease frequency delivered by the Global Organization for Research on Malignant growth state around the world, an expected 19.3 million new disease cases in 2020.

Besides, the rising interest for purpose in care testing (POCT) has been a significant driver of the flow cytometry market. POCT alludes to indicative testing performed at or close to the patient's area, giving quick and prompt outcomes. In this specific circumstance, flow cytometry has acquired conspicuousness because of its capacity to convey continuous, high-throughput examination of individual cells, making it a significant device for decentralized demonstrative settings.

Market Segmentation

The Flow Cytometry Market is divided into five segments based on components: software, services, reagents and consumables, accessories, cytometry platforms, and others. Additionally, the cytometry platform has been divided into two sections: cell sorters and cell analyzers; accessories, further divided into filter, laser, detectors, and other categories; and reagents and consumables, further divided into categories such as antibodies, dyes, beads, solution, buffer, and other categories. Based on technology the market is divided into bead-based flow cytometry and cell-based flow cytometry. The flow cytometry market is divided into two segments based on application: diagnosis applications and applications for academic and clinical research. Based on the end user, the market is divided into hospitals and clinics, businesses, clinical labs and medical schools, research institutes, and others.

Regional Insights

North America is likely to lead the market with high sending of logically progressed flow cytometry advancements, huge medical care spending, and deeply grounded medical services foundation in the region.

Europe flow cytometry market shows critical development during the figure year, i.e., 2022-2023, attributable to the rising ongoing sickness commonness, expanding need for new advances in the flow cytometry industry, which builds request, and rising interest in research and improvement, which prompts market extension.

The Asia-Pacific flow cytometry market is the fastest developing region because of the extending drug and biotechnology enterprises in rising economies like China and India. China's rising research commitments are because of the pattern of cytometry science and innovation being an outskirts multidisciplinary research subject, drawing in a great deal of research consideration from both scholarly world and industry. Also, in Australia, research and improvement drives keep on developing.

Major Players

Major Players in the Flow Cytometry Market are Cytek Biosciences, Inc. (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific, Inc. (US), Beckman Coulter, Inc. (US), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), Becton, Miltenyi Biotec (Germany), Sysmex Corporation (Japan), Dickinson, and Company (US), and Luminex Corporation (US).

Product Code: MRFR/MED/4972-CR

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
- 4.2.2 GROWING DEMAND FOR POINT-OF-CARE TESTING
- 4.2.3 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
4.3 RESTRAINTS
- 4.3.1 HIGH COST ASSOCIATED WITH FLOW CYTOMETRY INSTRUMENTS AND REAGENTS
- 4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
4.4 OPPORTUNITY
- 4.4.1 EXPANDING APPLICATIONS AND ADOPTION OF FLOW CYTOMETRY IN DIVERSE FIELDS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL FLOW CYTOMETRY MARKET
- 5.3.1 IMPACT ON THE GROWTH OF THE MARKET
- 5.3.2 IMPACT ON TRADE OF MAJOR MANUFACTURES
- 5.3.3 IMPACT IN MAJOR REGIONS
- 5.3.4 IMPACT IN IMPACT ON THE MANUFACTURING PROCESS

6 GLOBAL FLOW CYTOMETRY MARKET, BY COMPONENT

6.1 OVERVIEW
6.2 CYTOMETRY PLATFORM
- 6.2.1 CELL SORTERS
- 6.2.2 CELL ANALYSERS
6.3 ACCESSORIES
- 6.3.1 FILTER
- 6.3.2 LASER
- 6.3.3 DETECTORS
- 6.3.4 OTHERS
6.4 REAGENTS AND CONSUMABLES
- 6.4.1 ANTIBODIES
- 6.4.2 DYES
- 6.4.3 BEADS
- 6.4.4 SOLUTION
- 6.4.5 BUFFER
- 6.4.6 OTHERS
6.5 SOFTWARE
6.6 SERVICES

7 GLOBAL FLOW CYTOMETRY MARKET, BY TECHNOLOGY

7.1 OVERVIEW
7.2 BEAD BASED FLOW CYTOMETRY
7.3 CELL BASED FLOW CYTOMETRY

8 GLOBAL FLOW CYTOMETRY MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 ACADEMIC AND CLINICAL RESEARCH APPLICATIONS
- 8.2.1 CELL CYCLE ANALYSIS AND CELL PROLIFERATION
- 8.2.2 APOPTOSIS
- 8.2.3 SORTING AND SCREENING
- 8.2.4 TRANSFECTION AND CELL VIABILITY
- 8.2.5 OTHERS
8.3 DIAGNOSIS APPLICATIONS
- 8.3.1 CANCER
  - 8.3.1.1 LEUKEMIA
  - 8.3.1.2 LYMPHOMA
  - 8.3.1.3 OTHERS
- 8.3.2 IMMUNODEFICIENCY DISEASES
- 8.3.3 ORGAN TRANSPLATION
- 8.3.4 OTHERS

9 GLOBAL FLOW CYTOMETRY MARKET, BY END USER

9.1 OVERVIEW
9.2 HOSPITALS & CLINICS
9.3 COMMERCIAL ORGANIZATIONS
9.4 MEDICAL SCHOOLS AND CLINICAL LABS
9.5 RESEARCH INSTITUTES
9.6 OTHERS

10 GLOBAL FLOW CYTOMETRY MARKET, BY REGION

10.1 GLOBAL
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 SPAIN
- 10.3.5 ITALY
- 10.3.6 NETHERLANDS
- 10.3.7 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 JAPAN
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FLOW CYTOMETRY MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL FLOW CYTOMETRY MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
- 11.6.2 MERGER/ACQUISITION
- 11.6.3 PARTNERSHIP/COLLABORATION/AGREEMENT /EXPANSION
11.7 FINANCIAL MATRIX
- 11.7.1 SALES (USD BILLION), 2022
- 11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD BILLION), 2022

12 COMPANY PROFILES

12.1 THERMO FISHER SCIENTIFIC, INC.
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 SYSMEX CORPORATION
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 KEY STRATEGIES
12.3 BECKMAN COULTER, INC.
- 12.3.1 COMPANY OVERVIEWS
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 BECTON, DICKINSON AND COMPANY
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 MILTENYI BIOTEC
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 AGILENT TECHNOLOGIES, INC
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 CYTEK BIOSCIENCES
- 12.7.1 COMPANY OVERVIEWS
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 BIO-RAD LABORATORIES, INC.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 LUMINEX CORPORATION
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS/SERVICES OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 SARTORIUS AG
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS/SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES
13.2 RELATED REPORTS